China Hemodialysis and Peritoneal Dialysis Market

Fresenius Medical Care (Germany) is one of the Leading Players in the China Hemodialysis and Peritoneal Dialysis Market

The China hemodialysis and peritoneal dialysis market is projected to grow from an estimated USD 5.0 billion in 2019 to USD 7.4 billion by 2024, at a CAGR of 8.5% during the forecast period. Market growth is largely driven by factors such as increasing number of ESRD patients, growing prevalence of diabetes & hypertension (major causes of kidney failure), and preference for dialysis treatments over kidney transplants due to lack of donors. Furthermore, rise in the number of dialysis centers across China coupled with the increasing interest of market players to expand their network in the country through the acquisition of dialysis facilities is adding growth opportunities to the China hemodialysis and peritoneal dialysis market. Risks & complications associated with dialysis, low consumer awareness regarding kidney diseases, and reimbursement concerns are restricting the growth of this market to a certain extent.

The major players dominating the China hemodialysis and peritoneal dialysis market are Fresenius Medical Care AG & Co. KGaA (Germany), Baxter International, Inc. (US), and Shandong Weigao Group Medical Polymer Company Limited (China). Other players in this market include B. Braun Melsungen AG (Germany), Nikkiso Co. Ltd. (Japan), DaVita Healthcare Partners, Inc (US), Asahi Kasei Medical Co., Ltd (Japan), Bain Medical Equipment Co., Ltd. (China), Huaren Pharmaceutical (China), and Jiangsu Lengthen Life Science and Technology Co. Ltd (China). The analysis of the market developments between 2015 and 2019 revealed that several growth strategies such as product launches and strategic acquisitions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the hemodialysis and peritoneal dialysis market.

To know about the assumptions considered for the study download the pdf brochure

Fresenius Medical Care (Germany) is one of the leading players in the China hemodialysis and peritoneal dialysis market. Its broad portfolio of hemodialysis products & services is the key factor accounting for its large share in this market. As part of its growth strategy for the next 5 years (2023), the company aims to open ~100 renal hospitals and dialysis centers across the country. Furthermore, the company is focusing on providing dialysis facilities to patients across tier 2 and tier 3 cities in China (large and medium-sized cities with a population between 150,000 and 15 million, such as Kunming or Quanzhou). Fresenius is expanding its dialysis network in the country through the acquisition of dialysis facilities, including, two 70% stake acquisitions in hospitals in Sichuan Province and 55% stake acquisitions in Henan Aishen Hospital Management Co. Ltd. (Henan Aishen) and Aishen Beijing Hospital Management Co., Ltd. (Aishen Beijing). The company’s dialysis care network covers around 10 of the 32 provinces of China. The company is also focusing on opening new production sites across China. In this regard, its plant in Beijing, which manufactures dialysis concentrates, opened in 2018. The company is evaluating opportunities to collaborate with the public- and private-sector partners to expand its dialysis services business in China.

Shandong Weigao Group Medical Polymer Co., Ltd. (China), is a major local player offering dialysis products across China. The company has been focusing on widening access to dialysis treatments for lower- and middle-income households in China by substituting certain imported devices with locally manufactured devices. The major factor responsible for the large share of Shangding Weigao in the dialysis market in China is the expansion strategy of the company through the continued financing from investors such as International Finance Corporation (IFC) (a member of the World Bank Group). For instance, the company received USD 20 million loan in 2007 and about USD 96 million loan in 2015 from IFC to expand its supply of quality and affordable dialysis treatment across China.

Related Reports:

China Hemodialysis and Peritoneal Dialysis Market by Product & Services (HD, PD, Machine, Dialyzer, Concentrate, Dialysate, Catheter, Service), Modality (CAPD, APD, Nocturnal), End User (Hospital, Independent Center, Home Dialysis) - Forecast to 2024

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Report Code
MD 7158
RI Published ON
6/10/2019
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the China Hemodialysis and Peritoneal Dialysis Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved